# Codexis

machine-learning plus bioinformatics plus automated lab compress design-build-test to about one week, trained on 20+ years of experimental data.

Source: https://en.bioecon.ru/companies/codexis/
Updated: 2026-08-15

- Country: United States
- Ticker: CDXS

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | In July 2026, Codexis raised approximately $25 million in net proceeds through equity financing. (2026-06-30) | https://ir.codexis.com/news-events/press-releases/detail/452/codexis-reports-second-quarter-2026-financial-results, https://www.fool.com/earnings/call-transcripts/2026/08/18/codexis-cdxs-q2-2026-earnings-call-transcript/ |
| Capacity | Targeting 0.5 kilogram scale for siRNA production in the ECO Innovation Lab by the end of 2026; future GMP facility aims for larger scale. (2026-08-18) | https://www.fool.com/earnings/call-transcripts/2026/05/08/codexis-cdxs-q1-2026-earnings-transcript/, https://www.fool.com/earnings/call-transcripts/2026/08/18/codexis-cdxs-q2-2026-earnings-call-transcript/ |
| Certification | ISO 9001 certified for its in-house manufacturing suite. (2026-03-11) | https://ir.codexis.com/news-events/press-releases/detail/443/codexis-reports-fourth-quarter-and-fiscal-year-2025-financial-results, https://ir.codexis.com/sec-filings/all-sec-filings/content/0001200375-26-000006/cdxs-20251231.htm |
| Regulatory approval | Currently engaged with FDA's Emerging Technologies team regarding the ECO Synthesis platform; no product-specific commercial approvals cited. (2026-08-31) | https://www.fool.com/earnings/call-transcripts/2026/05/08/codexis-cdxs-q1-2026-earnings-transcript/, https://www.sec.gov/Archives/edgar/data/1200375/000119312526344646/d171403dex991.htm |
| Production site | Redwood City, California (headquarters/in-house manufacturing/ECO Innovation Lab); Hayward, California (future GMP manufacturing facility under construction). CMO facilities in Austria, Italy, and the UK. (2026-03-11) | https://ir.codexis.com/sec-filings/all-sec-filings/content/0001200375-26-000006/cdxs-20251231.htm, https://www.codexis.com/about-us/facilities/ |
| Headcount | 146 full-time and part-time employees. (2025-12-31) | https://ir.codexis.com/sec-filings/all-sec-filings/content/0001200375-26-000006/cdxs-20251231.htm |
| Revenue | $70.4 million for fiscal year 2025. (2025-12-31) | https://ir.codexis.com/news-events/press-releases/detail/443/codexis-reports-fourth-quarter-and-fiscal-year-2025-financial-results |

Independent sources: fool.com, sec.gov

## Technologies

- [Biocatalysis in petrochemistry](https://en.bioecon.ru/technology/biocatalysis-petrochemistry/)
- [Biosynthetic specialty & fine chemicals (precision fermentation, biocatalysis, biorefinery)](https://en.bioecon.ru/technology/biosynthetic-specialty-chemicals/)
- [Chemoenzymatic API synthesis (biocatalytic small-molecule manufacturing)](https://en.bioecon.ru/technology/chemoenzymatic-api-synthesis/)
- [Enzymatic polymer synthesis in vitro](https://en.bioecon.ru/technology/enzymatic-polymer-synthesis-in-vitro/)
- [Strain engineering (synbio CRO)](https://en.bioecon.ru/technology/strain-engineering-synbio-cro/)